Nyrada Past Earnings Performance

Past criteria checks 0/6

Nyrada has been growing earnings at an average annual rate of 1.6%, while the Pharmaceuticals industry saw earnings growing at 35.1% annually. Revenues have been growing at an average rate of 26.1% per year.

Key information

1.6%

Earnings growth rate

37.4%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate26.1%
Return on equity-27.5%
Net Margin-42.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Shareholders Will Probably Not Have Any Issues With Nyrada Inc.'s (ASX:NYR) CEO Compensation

Nov 12
Shareholders Will Probably Not Have Any Issues With Nyrada Inc.'s (ASX:NYR) CEO Compensation

Companies Like Nyrada (ASX:NYR) Can Afford To Invest In Growth

Jan 10
Companies Like Nyrada (ASX:NYR) Can Afford To Invest In Growth

We're Keeping An Eye On Nyrada's (ASX:NYR) Cash Burn Rate

Feb 23
We're Keeping An Eye On Nyrada's (ASX:NYR) Cash Burn Rate

Revenue & Expenses Breakdown

How Nyrada makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:NYR Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 243-130
31 Mar 243-330
31 Dec 233-530
30 Sep 232-630
30 Jun 231-830
31 Mar 232-630
31 Dec 222-430
30 Sep 222-430
30 Jun 221-430
31 Mar 222-430
31 Dec 212-440
30 Sep 212-440
30 Jun 212-430
31 Mar 212-540
31 Dec 201-650
30 Sep 201-650
30 Jun 201-650
31 Mar 201-540
31 Dec 190-430
30 Sep 190-430
30 Jun 190-430

Quality Earnings: NYR is currently unprofitable.

Growing Profit Margin: NYR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NYR is unprofitable, but has reduced losses over the past 5 years at a rate of 1.6% per year.

Accelerating Growth: Unable to compare NYR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NYR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (26.6%).


Return on Equity

High ROE: NYR has a negative Return on Equity (-27.54%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 19:50
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nyrada Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution